🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals at Risk of Nephropathy

Recruitingn/aAges 18 Years - anyAllUniversity Hospital, Grenoble
NCT07347769 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The aim of this observational study is to characterize the urinary replication of BK polyomavirus (BKV) in kidney transplant recipients. Although BKV reactivation after transplantation is well established, the origin of the replicating virus remains uncertain. Current evidence suggests that BKV detected in recipients may originate either from the transplanted kidney (donor-derived) or from viral reactivation in the recipient. The evaluation of new biomarkers to predict BKV replication are needed. This study seeks to address the following key questions: * Origin of the replicating virus: Is the BKV detected in the recipient identical to the virus originating from the donor kidney? * Host immune response and viral genotype: Is there an association between the recipient's immune response and the genotype of the replicating BKV? * Differences in immune response according to viral replicati

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Kidney transplant patients with a first positive BK virus viral load in urine. - BK virus viral load in urine \> 3 log copies/mL. * More than 3 months post-transplant and less than 2 years post-transplant. * Men or women aged 18 years and older. * Followed up at Grenoble Alpes University Hospital. * Affiliated with social security or beneficiary of such a scheme. * Patients who are not opposed to the TYPIK study. Exclusion Criteria: * Expected renal graft survival is \< 6 months, estimated by an eGFR \< 15 mL/min/1.73 m² at the time of BKPyV viruria * Patients who object to the use of their data and/or samples for research purposes * Subjects who are excluded from another study * Subjects under administrative or judicial supervision
💊

What it tests

  • Not listed
📍

Where

1 site
CHUGA
Grenoble, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy